Validity of administrative database detection of previously resolved hepatitis B virus in Japan

Shinobu Imai, Hayato Yamana, Norihiko Inoue, Manabu Akazawa, Hiromasa Horiguchi, Kiyohide Fushimi, Kiyoshi Migita, Hiroshi Yatsuhashi, Masaya Sugiyama, Masashi Mizokami

Research output: Contribution to journalArticle

Abstract

The risk of hepatitis B virus (HBV) reactivation has increased owing to advances in the immunosuppressive therapy field. However, the HBV reactivation incidence among patients with previously resolved HBV (prHBV) infection during immunosuppressive therapy for rheumatoid arthritis (RA) remains unclear. The objective of this work is to describe the validity of detecting prHBV infection from administrative data through comparisons with chart abstraction and determine the incidence of HBV reactivation during immunosuppressive therapy for RA in Japan. In this retrospective cohort study, data on selected patients were extracted from administrative claims data. To identify patients with prHBV infection and de novo hepatitis, and HBsAg carriers, we conducted chart abstraction. The incidence rate of de novo hepatitis was 1.23 of 100 person-years. The positive predictive value (PPV) and its 95% confidence interval (CI) of administrative data for the identification of suspected prHBV infections was 85.8% (95% CI: 81.7%-89.3%). This study evaluated the PPV of the algorithm of HBV-DNA testing with immunosuppressive therapy performed four times or more per year for the detection of prHBV infection from administrative data. Additionally, we determined the incidence rate of HBV reactivation among preHBV infections during immunosuppressive therapy for RA to be 1.23 of 100 person-years.

Original languageEnglish
Pages (from-to)1944-1948
Number of pages5
JournalJournal of medical virology
Volume91
Issue number11
DOIs
Publication statusPublished - 2019 Nov 1

Fingerprint

Hepatitis B virus
Immunosuppressive Agents
Japan
Databases
Infection
Rheumatoid Arthritis
Incidence
Hepatitis
Confidence Intervals
Therapeutics
Virus Diseases
Hepatitis B Surface Antigens
Cohort Studies
Retrospective Studies
DNA

Keywords

  • biostatistics and bioinformatics
  • chemotherapy
  • disease control
  • hepatitis B virus
  • infection
  • reactivation

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Validity of administrative database detection of previously resolved hepatitis B virus in Japan. / Imai, Shinobu; Yamana, Hayato; Inoue, Norihiko; Akazawa, Manabu; Horiguchi, Hiromasa; Fushimi, Kiyohide; Migita, Kiyoshi; Yatsuhashi, Hiroshi; Sugiyama, Masaya; Mizokami, Masashi.

In: Journal of medical virology, Vol. 91, No. 11, 01.11.2019, p. 1944-1948.

Research output: Contribution to journalArticle

Imai, S, Yamana, H, Inoue, N, Akazawa, M, Horiguchi, H, Fushimi, K, Migita, K, Yatsuhashi, H, Sugiyama, M & Mizokami, M 2019, 'Validity of administrative database detection of previously resolved hepatitis B virus in Japan', Journal of medical virology, vol. 91, no. 11, pp. 1944-1948. https://doi.org/10.1002/jmv.25540
Imai, Shinobu ; Yamana, Hayato ; Inoue, Norihiko ; Akazawa, Manabu ; Horiguchi, Hiromasa ; Fushimi, Kiyohide ; Migita, Kiyoshi ; Yatsuhashi, Hiroshi ; Sugiyama, Masaya ; Mizokami, Masashi. / Validity of administrative database detection of previously resolved hepatitis B virus in Japan. In: Journal of medical virology. 2019 ; Vol. 91, No. 11. pp. 1944-1948.
@article{6b928dac84424ffebc603667ad90b212,
title = "Validity of administrative database detection of previously resolved hepatitis B virus in Japan",
abstract = "The risk of hepatitis B virus (HBV) reactivation has increased owing to advances in the immunosuppressive therapy field. However, the HBV reactivation incidence among patients with previously resolved HBV (prHBV) infection during immunosuppressive therapy for rheumatoid arthritis (RA) remains unclear. The objective of this work is to describe the validity of detecting prHBV infection from administrative data through comparisons with chart abstraction and determine the incidence of HBV reactivation during immunosuppressive therapy for RA in Japan. In this retrospective cohort study, data on selected patients were extracted from administrative claims data. To identify patients with prHBV infection and de novo hepatitis, and HBsAg carriers, we conducted chart abstraction. The incidence rate of de novo hepatitis was 1.23 of 100 person-years. The positive predictive value (PPV) and its 95{\%} confidence interval (CI) of administrative data for the identification of suspected prHBV infections was 85.8{\%} (95{\%} CI: 81.7{\%}-89.3{\%}). This study evaluated the PPV of the algorithm of HBV-DNA testing with immunosuppressive therapy performed four times or more per year for the detection of prHBV infection from administrative data. Additionally, we determined the incidence rate of HBV reactivation among preHBV infections during immunosuppressive therapy for RA to be 1.23 of 100 person-years.",
keywords = "biostatistics and bioinformatics, chemotherapy, disease control, hepatitis B virus, infection, reactivation",
author = "Shinobu Imai and Hayato Yamana and Norihiko Inoue and Manabu Akazawa and Hiromasa Horiguchi and Kiyohide Fushimi and Kiyoshi Migita and Hiroshi Yatsuhashi and Masaya Sugiyama and Masashi Mizokami",
year = "2019",
month = "11",
day = "1",
doi = "10.1002/jmv.25540",
language = "English",
volume = "91",
pages = "1944--1948",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Validity of administrative database detection of previously resolved hepatitis B virus in Japan

AU - Imai, Shinobu

AU - Yamana, Hayato

AU - Inoue, Norihiko

AU - Akazawa, Manabu

AU - Horiguchi, Hiromasa

AU - Fushimi, Kiyohide

AU - Migita, Kiyoshi

AU - Yatsuhashi, Hiroshi

AU - Sugiyama, Masaya

AU - Mizokami, Masashi

PY - 2019/11/1

Y1 - 2019/11/1

N2 - The risk of hepatitis B virus (HBV) reactivation has increased owing to advances in the immunosuppressive therapy field. However, the HBV reactivation incidence among patients with previously resolved HBV (prHBV) infection during immunosuppressive therapy for rheumatoid arthritis (RA) remains unclear. The objective of this work is to describe the validity of detecting prHBV infection from administrative data through comparisons with chart abstraction and determine the incidence of HBV reactivation during immunosuppressive therapy for RA in Japan. In this retrospective cohort study, data on selected patients were extracted from administrative claims data. To identify patients with prHBV infection and de novo hepatitis, and HBsAg carriers, we conducted chart abstraction. The incidence rate of de novo hepatitis was 1.23 of 100 person-years. The positive predictive value (PPV) and its 95% confidence interval (CI) of administrative data for the identification of suspected prHBV infections was 85.8% (95% CI: 81.7%-89.3%). This study evaluated the PPV of the algorithm of HBV-DNA testing with immunosuppressive therapy performed four times or more per year for the detection of prHBV infection from administrative data. Additionally, we determined the incidence rate of HBV reactivation among preHBV infections during immunosuppressive therapy for RA to be 1.23 of 100 person-years.

AB - The risk of hepatitis B virus (HBV) reactivation has increased owing to advances in the immunosuppressive therapy field. However, the HBV reactivation incidence among patients with previously resolved HBV (prHBV) infection during immunosuppressive therapy for rheumatoid arthritis (RA) remains unclear. The objective of this work is to describe the validity of detecting prHBV infection from administrative data through comparisons with chart abstraction and determine the incidence of HBV reactivation during immunosuppressive therapy for RA in Japan. In this retrospective cohort study, data on selected patients were extracted from administrative claims data. To identify patients with prHBV infection and de novo hepatitis, and HBsAg carriers, we conducted chart abstraction. The incidence rate of de novo hepatitis was 1.23 of 100 person-years. The positive predictive value (PPV) and its 95% confidence interval (CI) of administrative data for the identification of suspected prHBV infections was 85.8% (95% CI: 81.7%-89.3%). This study evaluated the PPV of the algorithm of HBV-DNA testing with immunosuppressive therapy performed four times or more per year for the detection of prHBV infection from administrative data. Additionally, we determined the incidence rate of HBV reactivation among preHBV infections during immunosuppressive therapy for RA to be 1.23 of 100 person-years.

KW - biostatistics and bioinformatics

KW - chemotherapy

KW - disease control

KW - hepatitis B virus

KW - infection

KW - reactivation

UR - http://www.scopus.com/inward/record.url?scp=85072058424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072058424&partnerID=8YFLogxK

U2 - 10.1002/jmv.25540

DO - 10.1002/jmv.25540

M3 - Article

VL - 91

SP - 1944

EP - 1948

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 11

ER -